Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Eli Lilly reported promising results from a study ... But it is unclear whether the nation’s health secretary, Robert F. Kennedy Jr., will weigh in; doing so would be highly unusual.

The Lilly Endowment is a private philanthropic foundation formed by J. K. Lilly, Sr., and his sons Eli and J. K., Jr., through gifts of stock in their pharmaceutical company, Eli Lilly.

While arch rival Eli Lilly and Company (LLY ... abrupt appointment and regulatory changes following RFK Jr.’s appointment as HHS Secretary, just to name a few. As I indicated in my previous ...

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not ...